Grail's Stock Drops 16% Following ASCO Presentation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Fool
- Significant Stock Decline: Grail's stock fell 16% to $62.93, with a market cap of $3.1 billion, indicating a negative market reaction to the data presented at the ASCO Annual Meeting, undermining investor confidence in FDA approval and insurer adoption.
- Trial Results Mixed: The Galleri test failed to significantly reduce late-stage cancer detection rates in a three-year trial with the NHS, although management claimed a 'substantial and clinically meaningful reduction' in Stage IV diagnoses compared to standard care, yet the market remained unimpressed.
- Sensitivity Data Insights: The Galleri test detected cancer in 287 participants, with 173 later diagnosed, resulting in a 60.3% positive result confirmation rate; however, the overall sensitivity for all cancers was only 39.3%, raising concerns about its effectiveness among investors.
- Investor Opportunity: Despite the aggressive market sell-off, investors might consider focusing on the 69.8% sensitivity for the 12 key cancers detected by the Galleri test, suggesting that if insurers share this perspective, today's decline could present a buying opportunity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 61.130
Low
38.00
Averages
60.86
High
83.71
Current: 61.130
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail's Stock Drops 16% Following ASCO Presentation
- Significant Stock Decline: Grail's stock fell 16% to $62.93, with a market cap of $3.1 billion, indicating a negative market reaction to the data presented at the ASCO Annual Meeting, undermining investor confidence in FDA approval and insurer adoption.
- Trial Results Mixed: The Galleri test failed to significantly reduce late-stage cancer detection rates in a three-year trial with the NHS, although management claimed a 'substantial and clinically meaningful reduction' in Stage IV diagnoses compared to standard care, yet the market remained unimpressed.
- Sensitivity Data Insights: The Galleri test detected cancer in 287 participants, with 173 later diagnosed, resulting in a 60.3% positive result confirmation rate; however, the overall sensitivity for all cancers was only 39.3%, raising concerns about its effectiveness among investors.
- Investor Opportunity: Despite the aggressive market sell-off, investors might consider focusing on the 69.8% sensitivity for the 12 key cancers detected by the Galleri test, suggesting that if insurers share this perspective, today's decline could present a buying opportunity.
See More
Galleri Test Increases Cancer Detection by 6.5 Times
- Detection Efficiency Boost: The Galleri Multi-Cancer Early Detection test increased cancer detection rates by 6.5 times when added to recommended screenings, demonstrating significant advantages in early cancer identification, particularly for breast, colorectal, cervical, and lung cancers.
- Early Detection Capability: Of the new cancers detected by the Galleri test, 71% were in stages I-II, indicating the test's strong ability to identify cancers at early stages, thereby providing patients with better treatment opportunities.
- Clinical Research Findings: GRAIL presented the full data from its PATHFINDER 2 study, which included 35,878 participants, at the 2026 American Society of Clinical Oncology Annual Meeting, further validating the effectiveness and safety of the Galleri test.
- Market Potential: As the demand for early cancer detection rises, the success of the Galleri test is likely to enhance GRAIL's competitiveness in the healthcare market, potentially leading to significant revenue growth and increased market share.
See More
Galleri Blood Test Significantly Improves Early Cancer Detection Rates
- Significant Screening Impact: The Galleri blood test reduced Stage IV diagnoses of 12 prespecified cancers by 22% and 26% in the second and third screening rounds, respectively, highlighting its critical role in early cancer detection.
- Detection Rate Enhancement: When combined with standard care screening, the Galleri test increased cancer detection rates four-fold and reduced cancer diagnoses through emergency presentation by 25%, demonstrating its effectiveness in clinical applications.
- Increased Early Diagnoses: Annual testing with Galleri led to a 16% increase in Stage I-II cancer diagnoses, providing more opportunities for early intervention that could improve patient outcomes.
- Industry Attention: GRAIL will host an analyst call from the 2026 ASCO Annual Meeting to further discuss the clinical utility and safety of Galleri, which is expected to attract significant interest from investors and the medical community.
See More
Grail's 20% Stock Decline Hides Potential Opportunities
- Trial Endpoint Failure: Grail's multicancer early detection test, Galleri, missed its primary endpoint in a landmark three-year, 142,000-person trial with the NHS, resulting in over a 20% stock decline in 2026, leading investors to doubt FDA approval and insurance coverage prospects.
- Sales Growth Momentum: Despite the disappointing trial results, Grail reported a 37% year-over-year increase in Galleri test sales in Q1 2026, with volumes rising 50% to 56,000, indicating growing market acceptance and demand that could lay the groundwork for future recovery.
- Follow-Up Data Outlook: Management anticipates that follow-up data six to twelve months post-trial will demonstrate the test's efficacy, particularly with detailed trial data to be presented at the ASCO meeting, which may influence physician and insurer decisions regarding Galleri's market acceptance.
- Insurance Coverage Potential: While the NHS-Galleri trial faced criticism for not meeting endpoints, the underlying data and ASCO presentation may support insurance coverage for Galleri, attracting risk-seeking investors interested in the stock's potential value.
See More
Grail Stock Volatility and Future Outlook
- Stock Volatility: Grail's stock was spun off from Illumina in June 2024, starting at $13.95 per share and peaking at $116.06 on January 22, 2026, but now trades around $60, indicating market concerns about its future prospects.
- Trial Result Failure: Grail's Galleri blood test missed its primary endpoint in the largest NHS trial, prompting Canaccord Genuity to lower its price target from $105 to $80, reflecting investor disappointment in its potential.
- Revenue Growth and Losses: Despite Grail's revenue increasing from $93 million in 2023 to $147 million in 2025, with net losses narrowing from $1.47 billion to $408 million, analysts expect revenue to rise 25% to $224 million in 2027, with losses widening to $485 million, indicating ongoing profitability challenges.
- Uncertain Market Outlook: While Galleri has significant sales potential if FDA approval and insurance coverage are achieved, the NHS trial results suggest these catalysts may not materialize soon, requiring investors to approach this speculative opportunity with caution.
See More
Grail Shares Rise 14% Following Q1 Earnings Report
- Earnings Report Surge: Grail's stock rose 14% following its Q1 earnings report, despite a nearly 28% decline this year, indicating a market reassessment of its future potential.
- Clinical Trial Challenges: Although the trial failed to meet its primary endpoint, causing a stock crash in February, management plans to extend the follow-up period by 6-12 months to potentially improve outcomes and seek FDA approval.
- Testing Volume Growth: Galleri test volumes increased by 50% year-over-year, driving overall company revenue growth of 28% in Q1, demonstrating strong market demand for the product.
- ASCO Meeting Outlook: Grail will present detailed trial results at the ASCO meeting in late May, which could be pivotal for market acceptance, warranting investor attention.
See More
Grail's Stock Drops 16% Following ASCO Presentation
- Significant Stock Decline: Grail's stock fell 16% to $62.93, with a market cap of $3.1 billion, indicating a negative market reaction to the data presented at the ASCO Annual Meeting, undermining investor confidence in FDA approval and insurer adoption.
- Trial Results Mixed: The Galleri test failed to significantly reduce late-stage cancer detection rates in a three-year trial with the NHS, although management claimed a 'substantial and clinically meaningful reduction' in Stage IV diagnoses compared to standard care, yet the market remained unimpressed.
- Sensitivity Data Insights: The Galleri test detected cancer in 287 participants, with 173 later diagnosed, resulting in a 60.3% positive result confirmation rate; however, the overall sensitivity for all cancers was only 39.3%, raising concerns about its effectiveness among investors.
- Investor Opportunity: Despite the aggressive market sell-off, investors might consider focusing on the 69.8% sensitivity for the 12 key cancers detected by the Galleri test, suggesting that if insurers share this perspective, today's decline could present a buying opportunity.
See More
Galleri Test Increases Cancer Detection by 6.5 Times
- Detection Efficiency Boost: The Galleri Multi-Cancer Early Detection test increased cancer detection rates by 6.5 times when added to recommended screenings, demonstrating significant advantages in early cancer identification, particularly for breast, colorectal, cervical, and lung cancers.
- Early Detection Capability: Of the new cancers detected by the Galleri test, 71% were in stages I-II, indicating the test's strong ability to identify cancers at early stages, thereby providing patients with better treatment opportunities.
- Clinical Research Findings: GRAIL presented the full data from its PATHFINDER 2 study, which included 35,878 participants, at the 2026 American Society of Clinical Oncology Annual Meeting, further validating the effectiveness and safety of the Galleri test.
- Market Potential: As the demand for early cancer detection rises, the success of the Galleri test is likely to enhance GRAIL's competitiveness in the healthcare market, potentially leading to significant revenue growth and increased market share.
See More
Galleri Blood Test Significantly Improves Early Cancer Detection Rates
- Significant Screening Impact: The Galleri blood test reduced Stage IV diagnoses of 12 prespecified cancers by 22% and 26% in the second and third screening rounds, respectively, highlighting its critical role in early cancer detection.
- Detection Rate Enhancement: When combined with standard care screening, the Galleri test increased cancer detection rates four-fold and reduced cancer diagnoses through emergency presentation by 25%, demonstrating its effectiveness in clinical applications.
- Increased Early Diagnoses: Annual testing with Galleri led to a 16% increase in Stage I-II cancer diagnoses, providing more opportunities for early intervention that could improve patient outcomes.
- Industry Attention: GRAIL will host an analyst call from the 2026 ASCO Annual Meeting to further discuss the clinical utility and safety of Galleri, which is expected to attract significant interest from investors and the medical community.
See More
Grail's 20% Stock Decline Hides Potential Opportunities
- Trial Endpoint Failure: Grail's multicancer early detection test, Galleri, missed its primary endpoint in a landmark three-year, 142,000-person trial with the NHS, resulting in over a 20% stock decline in 2026, leading investors to doubt FDA approval and insurance coverage prospects.
- Sales Growth Momentum: Despite the disappointing trial results, Grail reported a 37% year-over-year increase in Galleri test sales in Q1 2026, with volumes rising 50% to 56,000, indicating growing market acceptance and demand that could lay the groundwork for future recovery.
- Follow-Up Data Outlook: Management anticipates that follow-up data six to twelve months post-trial will demonstrate the test's efficacy, particularly with detailed trial data to be presented at the ASCO meeting, which may influence physician and insurer decisions regarding Galleri's market acceptance.
- Insurance Coverage Potential: While the NHS-Galleri trial faced criticism for not meeting endpoints, the underlying data and ASCO presentation may support insurance coverage for Galleri, attracting risk-seeking investors interested in the stock's potential value.
See More
Grail Stock Volatility and Future Outlook
- Stock Volatility: Grail's stock was spun off from Illumina in June 2024, starting at $13.95 per share and peaking at $116.06 on January 22, 2026, but now trades around $60, indicating market concerns about its future prospects.
- Trial Result Failure: Grail's Galleri blood test missed its primary endpoint in the largest NHS trial, prompting Canaccord Genuity to lower its price target from $105 to $80, reflecting investor disappointment in its potential.
- Revenue Growth and Losses: Despite Grail's revenue increasing from $93 million in 2023 to $147 million in 2025, with net losses narrowing from $1.47 billion to $408 million, analysts expect revenue to rise 25% to $224 million in 2027, with losses widening to $485 million, indicating ongoing profitability challenges.
- Uncertain Market Outlook: While Galleri has significant sales potential if FDA approval and insurance coverage are achieved, the NHS trial results suggest these catalysts may not materialize soon, requiring investors to approach this speculative opportunity with caution.
See More
Grail Shares Rise 14% Following Q1 Earnings Report
- Earnings Report Surge: Grail's stock rose 14% following its Q1 earnings report, despite a nearly 28% decline this year, indicating a market reassessment of its future potential.
- Clinical Trial Challenges: Although the trial failed to meet its primary endpoint, causing a stock crash in February, management plans to extend the follow-up period by 6-12 months to potentially improve outcomes and seek FDA approval.
- Testing Volume Growth: Galleri test volumes increased by 50% year-over-year, driving overall company revenue growth of 28% in Q1, demonstrating strong market demand for the product.
- ASCO Meeting Outlook: Grail will present detailed trial results at the ASCO meeting in late May, which could be pivotal for market acceptance, warranting investor attention.
See More
